OP-ED: WCW & Rep. Boyle Join Forces to Cut FDA Animal Testing Red Tape

Posted by Amanda Nieves
05 May 2021 | Blog, Transparency

It’s shocking but true: FDA red tape is FORCING drug makers to poison puppies in wasteful tests even when high-tech alternatives are available and companies would prefer to use them.

Fortunately, we’re working with two-time WCW Waste Warrior awardee Congressman Brendan Boyle (D-PA) to cut this deadly red tape by passing the bipartisan AARF Act.

Now, in the influential Capitol Hill publication Roll Call, Rep. Boyle and WCW VP Justin Goodman explain why cutting FDA red tape will help puppies, patients and pharmaceutical companies working to develop cures.

Check out the op-ed below, and then take action.

Times, and technologies, are changing. With growing momentum in the movement to stop harmful animal testing and major advancements in alternative research methods, it’s time to right the wrongs of the past.

Animal testing is not nearly as accurate as scientific alternatives, and certainly much less humane. Yet, the Food and Drug Administration requires it for certain approvals. We’re here to change that.

Researchers from the Hebrew University of Jerusalem recently submitted for FDA approval the first drug developed using high-tech research tools and absolutely no animal testing. This is a major breakthrough and should become the rule at the FDA, not the exception.

As many as one-third of all dogs subjected to experiments each year are tested on to fulfill outdated regulatory requirements from the FDA and other federal agencies. As White Coat Waste Project has documented, in some of the standard tests the FDA compels companies to conduct, puppies as young as 1 week old are forced to ingest massive doses of experimental drugs, often resulting in convulsion and death.

Animal testing isn’t just inhumane, it’s also incredibly expensive. Researchers at Hebrew University found that while it normally takes four to six years and millions of dollars to bring a drug to clinical trial using animal testing practices, it only took them eight months, at a fraction of the cost, when using science-based testing methods. Estimates say drug development costs could be cut by over a quarter with more expanded use of non-animal testing tools.

Recently, drugmakers have begun developing and embracing new technologies built from human cells and tissues. Researchers from the University of Pennsylvania and elsewhere have shown that these 21st-century methods are more accurate at predicting how drugs will behave in humans than animal tests.

In some cases, the FDA has reportedly allowed companies to bypass some animal testing prior to initiating human trials, leading to the expedited review and approval of several effective COVID-19 vaccines now in widespread use. Yet, in other instances, drugmakers state that they were directed by the agency to conduct unnecessary and expensive testing on dogs without any scientific basis.

Part of the current problem is that FDA rules about what animal tests are actually required are unclear and lack a well-defined and transparent process for companies to propose alternatives. The agency has repeatedly failed to answer Congress’ questions about this.

So, drugmakers often end up conducting needless animal tests, even when they would prefer to use more effective and efficient alternatives. The National Institutes of Health estimates that over 90 percent of drugs fail in human trials because animal tests don’t accurately predict their safety or effectiveness.

The NIH admitted that “animal models often fail to provide good ways to mimic disease or predict how drugs will work in humans, resulting in much wasted time and money while patients wait for therapies.” This problem is particularly apparent now as we continue confronting the COVID-19 pandemic. One team of researchers recently remarked, “Scientists worldwide struggle to identify suitable animal models to study SARS-CoV-2. … Especially for human diseases with an urgent medical need and a lack of suitable in vivo models, human-based models may expedite clinical translation.”

Americans want the government to do better. A March national poll of 1,000 voters conducted by Lincoln Park Strategies found that 64 percent of people believe drug companies should be allowed to use alternatives to animal testing whenever possible. So do we.

That’s why we’re working together to pass the bipartisan Alternatives to Animals for Regulatory Fairness Act — the AARF Act, for short — to update federal law to clearly allow drugmakers to use alternatives to animal testing to meet FDA drug screening requirements.

For the benefit of human patients and lab animals, companies should be allowed to innovate and use the most cutting-edge drug development tools instead of being compelled by the government to abuse animals in painful, outdated, and inefficient experiments.

Rep. Brendan F. Boyle is a Democrat representing Pennsylvania’s 2nd District. He serves on the House Budget and Ways and Means committees.
Justin Goodman is the vice president of advocacy and public policy at the White Coat Waste Project, a 3-million-member taxpayer watchdog group.

Add a comment

*Please complete all fields correctly

Related Blogs

Posted by anieves | 14 June 2024
  Citing WCW exposés and campaigns, the House unanimously passed bipartisan legislation defunding the Defense Department’s dog and cat testing. The bill marks the first time Congress has voted to...
Posted by anieves | 12 June 2024
  In a shocking turn of events, the Washington Post has admitted it published disinformation fed to it by NIH to discredit White Coat Waste Project and defend Fauci from...
Posted by anieves | 12 June 2024
  Following White Coat Waste Project (WCW) investigations and lobbying, Congress is renewing its push to defund gain-of-function animal experiments, disgraced Wuhan lab funder EcoHealth Alliance (EHA), and animal labs...